Results 71 to 80 of about 45,492 (265)

Mineralocorticoid receptor activation in obesity hypertension [PDF]

, 2009
Miki Nagase, Toshiro Fujita
openalex   +1 more source

FDG PET/CT imaging and circulating biomarkers of inflammation in desmoplakin cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1485-1489, April 2025.
Abstract Aims Inflammation has been implicated in the pathogenesis of desmoplakin (DSP) cardiomyopathy, and retrospective studies have described abnormal myocardial fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings in symptomatic patients eventually diagnosed with DSP cardiomyopathy.
Sanjay Divakaran, Vinay Randhawa, Usman A. Tahir, Matthew Robertson, Anam A. Waheed, Anna Perillo, Leanne Barrett, Ron Blankstein, Mark W. Feinberg, Marcelo F. Di Carli, Neal K. Lakdawala   +10 more
wiley   +1 more source

Crystal structure of the mineralocorticoid receptor DNA binding domain in complex with DNA.

PLoS ONE, 2014
The steroid hormone receptors regulate important physiological functions such as reproduction, metabolism, immunity, and electrolyte balance. Mutations within steroid receptors result in endocrine disorders and can often drive cancer formation and ...
William H Hudson, Christine Youn, Eric A Ortlund   +2 more
doaj   +1 more source

Case Report: Application of whole exome sequencing for accurate diagnosis of rare syndromes of mineralocorticoid excess [version 2; referees: 2 approved]

F1000Research, 2017
Syndromes of mineralocorticoid excess (SME) are closely related clinical manifestations occurring within a specific set of diseases. Overlapping clinical manifestations of such syndromes often create a dilemma in accurate diagnosis, which is crucial for ...
Ranjit Narayanan, Shamsudheen Karuthedath Vellarikkal, Rijith Jayarajan, Ankit Verma, Vishal Dixit, Vinod Scaria, Sridhar Sivasubbu   +6 more
doaj   +1 more source

Salt and aldosterone do not get along with each other: implication of mineralocorticoid receptors in the profibrotic action of aldosterone [PDF]

, 2011
Decio Armanini, Lorenzo A. Calò, Cristina Fiore   +2 more
openalex   +1 more source

FIDELIO study: significance and place of finerenone as nonsteroidal mineralocorticoid receptor antagonist in therapy of patients with chronic kidney disease in type 2 diabetes [PDF]

, 2023
Минара Шамхаловна Шамхалова, O. Y. Sukhareva, M. I. Yevloyeva   +2 more
openalex   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Aldosterone Synthase Inhibitors for Cardiorenal Protection: Ready for Prime Time?

Kidney & Blood Pressure Research
Background: Aldosterone is the principal mineralocorticoid hormone and the final effector of the renin-angiotensin-aldosterone system. This hormone is primarily synthesized by the CYP11B2 enzyme and produced by the adrenal zona glomerulosa ...
Alessio Mazzieri, Francesca Timio, Francesco Patera, Francesco Trepiccione, Mario Bonomini, Gianpaolo Reboldi   +5 more
doaj   +1 more source

Temporal trends in initiation of mineralocorticoid receptor antagonists and risk of subsequent withdrawal in patients with heart failure: a nationwide study in Denmark from 2003–2017 [PDF]

, 2021
Deewa Zahir, Anders Nissen Bonde, Christian Madelaire, Morten Malmborg, Jawad H. Butt, Emil Loldrup Fosbøl, Gunnar Gislason, Christian Torp‐Pedersen, Charlotte Andersson, Patrick Rossignol, John J.V. McMurray, Lars Køber, Morten Schou   +12 more
openalex   +1 more source

Effect of Mineralocorticoid receptor antagonism (MRA) on aldosterone-interleukin 6 axis in heart failure; second opinion. A case-control study

The Egyptian Journal of Internal Medicine
Background In cases of heart failure characterized by reduced ejection fraction (HFrEF), heightened levels of aldosterone negatively impact the progression of heart failure.
H. ElSawi, S. Zidan, A. Elborolosy
doaj   +1 more source